On this page

Miconazole Nitrate

ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Miconazole Nitrate
Generic name
Miconazole Nitrate
Dosage form
Suppository
Route
Vaginal
Marketing category
DRUG FOR FURTHER PROCESSING · BULK API
Labeler
Swiss Caps AG
Product type
Drug For Further Processing
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
4
Packages
4
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Miconazole Nitrate 1200 mg/1 992765 View
Miconazole Nitrate 200 mg/1 992765 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Suppository
Route of administration
Vaginal
Presentations
8

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Azole Antifungal [EPC] EPC All 44 members
Azoles [CS] CS All 44 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
073508
Application type
ANDA · Abbreviated New Drug Application
Approval date
November 19, 1993
Sponsor
ACTAVIS PHARMA
Products on application
1
Submissions recorded
13
Products approved under application 073508.
Product Trade name Form Strength Ingredient Status TE Flags
073508-001 MICONAZOLE NITRATE SUPPOSITORY MICONAZOLE NITRATE Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 073508.
Type No. Action Status Date Review
Supplement 15 Manufacturing (CMC) Approved July 9, 2002 —
Supplement 14 Manufacturing (CMC) Approved January 8, 2002 —
Supplement 13 Manufacturing (CMC) Approved December 29, 2000 —
Supplement 12 Manufacturing (CMC) Approved January 9, 1998 —
Supplement 7 Manufacturing (CMC) Approved October 11, 1996 —
Supplement 9 Manufacturing (CMC) Approved July 24, 1996 —
Supplement 6 Manufacturing (CMC) Approved July 24, 1996 —
Supplement 5 Manufacturing (CMC) Approved July 24, 1996 —
Supplement 4 Manufacturing (CMC) Approved July 24, 1996 —
Supplement 8 Manufacturing (CMC) Approved June 28, 1996 —
Supplement 2 Manufacturing (CMC) Approved May 15, 1995 —
Supplement 1 Manufacturing (CMC) Approved January 30, 1995 —
Original application 1 Approved November 19, 1993 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20201021). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20201021

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Miconazole Nitrate Vaginal Suppositories USP, 200 mg are indicated for the local treatment of vulvovaginal candidiasis (moniliasis). Effectiveness in pregnancy has not been established. As miconazole nitrate is effective only for candidal vulvovaginitis, the diagnosis should be confirmed by KOH smear and/or cultures. Other pathogens commonly associated with vulvovaginitis ( Trichomonas and Haemophilus vaginalis [Gardnerella] ) should be ruled out by appropriate laboratory methods.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Miconazole Nitrate Vaginal Suppositories USP, 200 mg: One suppository (miconazole nitrate, 200 mg) is inserted intravaginally once daily at bedtime for three consecutive days. Before prescribing another course of therapy, the diagnosis should be reconfirmed by smears and/or cultures to rule out other pathogens.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Patients known to be hypersensitive to this drug.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS During clinical studies with Miconazole Nitrate Vaginal Suppositories USP, 200 mg, 301 patients were treated. The incidence of vulvovaginal burning, itching or irritation was 2%. Complaints of cramping (2%) and headaches (1 . 3%) were also reported. Other complaints (hives, skin rash) occurred with less than a 0 . 5% incidence. The therapy-related dropout rate was 0 . 3%. To report SUSPECTED ADVERSE EVENTS, contact Teva Pharmaceuticals USA, Inc., at 1-888-838-2872 or FDA at 1-800-FDA-1088 or http://www.fda.gov/ for voluntary reporting of adverse reactions.

Description

openFDA Drug Labeling

DESCRIPTION Miconazole Nitrate Vaginal Suppositories USP, 200 mg are white to off-white suppositories, each containing the antifungal agent, miconazole nitrate, USP 1-[2,4-Dichloro-β-[(2,4- dichlorobenzyl)oxy] phenethyl]-imidazole mononitrate, 200 mg, in a hydrogenated vegetable oil base. The molecular formula is C 18 H 14 Cl 4 N 2 O•HNO 3 ; the molecular weight is 479.14 and the structural formula may be represented as follows: 009711be-figure-01

​OVERDOSAGE Overdosage of miconazole nitrate in humans has not been reported to date. In mice, rats, guinea pigs and dogs, the oral LD 50 values were found to be 578 . 1, greater than 640, 275 . 9 and greater than 160 mg/kg, respectively.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Miconazole Nitrate Vaginal Suppositories USP, 200 mg are available as elliptically shaped white to off-white suppositories in packages of three with a vaginal applicator NDC 0472-1738-03. Store at controlled room temperature 15° to 30°C (59° to 86°F). Manufactured for: Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054 Rev. A 7/2020

Adverse event reports

Source: openFDA FAERS
8,749
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: MICONAZOLE NITRATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0472-1738-03 0472-1738 Actavis Pharma, Inc. 3 SUPPOSITORY in 1 CARTON (0472-1738-03) January 18, 1995
11014-0343-1 11014-0343 Catalent Pharma Solutions, LLC 1 BAG in 1 CONTAINER (11014-0343-1) / 2000 SUPPOSITORY in 1 BAG December 10, 2009
65655-0013-1 65655-0013 Swiss Caps AG 2 BAG in 1 CARTON (65655-0013-1) / 1200 SUPPOSITORY in 1 BAG June 29, 2001
65655-0014-1 65655-0014 Swiss Caps AG 2 BAG in 1 CARTON (65655-0014-1) / 1200 SUPPOSITORY in 1 BAG April 16, 1996
0472-1738 0472-1738 Actavis Pharma, Inc. — January 18, 1995
11014-0343 11014-0343 Catalent Pharma Solutions, LLC — December 10, 2009
65655-0013 65655-0013 Swiss Caps AG — June 29, 2001
65655-0014 65655-0014 Swiss Caps AG — April 16, 1996

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.